However, given the lack of reliable animal models that recapitulate plaque rupture [67], and the lack of clinical studies directly investigating the effect of TGF-β inhibition in a population with high risk for CAD, it is difficult to draw conclusions regarding the clinical importance of TGF-β for stabilizing atherosclerotic plaques. The gene discussed is TGFB1; the disease is coronary artery disorder.